{"id":"pregabalin-release-tablets","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Somnolence"},{"rate":"5-15","effect":"Dry mouth"},{"rate":"5-10","effect":"Edema"},{"rate":"5-10","effect":"Blurred vision"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5-10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1059","moleculeType":"Small molecule","molecularWeight":"159.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pregabalin is an anticonvulsant and anxiolytic agent that modulates calcium channel activity by binding to the alpha-2-delta-1 subunit, thereby decreasing calcium influx and subsequent neurotransmitter release. This mechanism reduces neuronal hyperexcitability and is effective in treating neuropathic pain, epilepsy, and anxiety disorders. The extended-release tablet formulation aims to provide sustained therapeutic levels with improved dosing convenience.","oneSentence":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:02.831Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury pain)"},{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Generalized anxiety disorder"},{"name":"Fibromyalgia"}]},"trialDetails":[{"nctId":"NCT06935721","phase":"PHASE1","title":"Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in Chinese Healthy Subject","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-03-28","conditions":"Healthy Male and Female Subjects","enrollment":10},{"nctId":"NCT06383702","phase":"PHASE3","title":"A Study to Evaluate Pregabalin in Painful Diabetic Peripheral Neuropathy","status":"NOT_YET_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2024-05-15","conditions":"Painful Diabetic Neuropathy","enrollment":358},{"nctId":"NCT05624853","phase":"PHASE4","title":"A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2020-05-12","conditions":"Neuropathic Pain, Diabetes Mellitus, Type 2","enrollment":130},{"nctId":"NCT06025474","phase":"PHASE3","title":"Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2023-01-01","conditions":"Burning Mouth Syndrome","enrollment":203},{"nctId":"NCT05389813","phase":"PHASE2, PHASE3","title":"Comparison Between Oxycodone and Pregabalin as Preemptive Analgesia","status":"UNKNOWN","sponsor":"An-Najah National University","startDate":"2021-08-15","conditions":"Anesthesia","enrollment":150},{"nctId":"NCT04171453","phase":"","title":"Post-marketing Surveillance (PMS) to Observe the Safety and Effectiveness of Lyrica CR Extended Release Tablets","status":"UNKNOWN","sponsor":"Viatris Korea","startDate":"2020-02-03","conditions":"Peripheral Neuropathic Pain","enrollment":600},{"nctId":"NCT01080612","phase":"PHASE1","title":"A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT01270828","phase":"PHASE3","title":"Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-03","conditions":"Post Herpetic Neuralgia","enrollment":806},{"nctId":"NCT01262677","phase":"PHASE3","title":"Once-A-Day Pregabalin For Partial Seizures","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-02-17","conditions":"Partial Seizures, Epilepsies, Partial","enrollment":325},{"nctId":"NCT01291524","phase":"PHASE1","title":"Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted At Bedtime Or Immediately Following A 400-500 or 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-02","conditions":"Healthy","enrollment":24},{"nctId":"NCT01342198","phase":"PHASE1","title":"An Investigation of the Effects of Erythromycin on the Pharmacokinetics of the Pregabalin Controlled Release Tablet","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-06","conditions":"Healthy","enrollment":18},{"nctId":"NCT01202422","phase":"PHASE1","title":"An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-10","conditions":"Healthy","enrollment":24},{"nctId":"NCT01321671","phase":"PHASE1","title":"Investigation Of Absorption And Pharmacokinetics Of A Single Dose Of Controlled Release Pregabalin Tablet Administered Fasted In The Evening or Immediately Following A 600-750 Calorie Evening Meal As Compared To Single Dose Of Immediate Release Pregabalin Capsule In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT01271933","phase":"PHASE3","title":"Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-03","conditions":"Fibromyalgia","enrollment":441},{"nctId":"NCT01270815","phase":"PHASE1","title":"An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following Various Sized Lunches As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-03","conditions":"Healthy","enrollment":28},{"nctId":"NCT01257516","phase":"PHASE1","title":"An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-02","conditions":"Healthy","enrollment":18},{"nctId":"NCT01257529","phase":"PHASE1","title":"An Investigation Of The Absorption And Pharmacokinetics Of A Single Dose Of A Controlled Release (CR) Pregabalin Tablet Following A Low, Medium, And High-Fat Evening Meal As Compared To A Single Dose Of The Immediate Release (IR) Pregabalin Capsule In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-03","conditions":"Healthy","enrollment":28},{"nctId":"NCT01202435","phase":"PHASE1","title":"An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of A Controlled Release Pregabalin Tablet As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-10","conditions":"Healthy","enrollment":18},{"nctId":"NCT01443169","phase":"PHASE1","title":"A 5-treatment, Study in Healthy Volunteers to Assess The Safety, Tolerability, and Pharmacokinetics of Four Controlled Release (CR) Pregabalin Tablet Formulations and the Immediate Release (IR) Formulation Administered Fasted","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2012-03","conditions":"Healthy","enrollment":16},{"nctId":"NCT01220219","phase":"PHASE1","title":"An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2010-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT01009541","phase":"PHASE1","title":"An Investigation of the Absorption and Pharmacokinetics of Multiple Doses of Three Controlled Release Pregabalin Tablets as Compared to Multiple Doses of the Immediate Release Pregabalin Capsule","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2009-11","conditions":"Healthy","enrollment":20},{"nctId":"NCT02725112","phase":"PHASE1","title":"Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2016-02-12","conditions":"Healthy","enrollment":25},{"nctId":"NCT02952937","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2016-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT02955472","phase":"PHASE1","title":"Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2016-11","conditions":"Healthy","enrollment":24},{"nctId":"NCT02868814","phase":"PHASE3","title":"The Efficacy and Safety of Pregabalin Release Tablets for the Treatment of Fibromyalgia","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2016-05","conditions":"Fibromyalgia","enrollment":240},{"nctId":"NCT02868801","phase":"PHASE3","title":"Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-03","conditions":"Postherpetic Neuralgia","enrollment":280},{"nctId":"NCT02326987","phase":"PHASE1","title":"A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS-NF1 Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2013-10","conditions":"Healthy","enrollment":30},{"nctId":"NCT01638273","phase":"PHASE1","title":"PK Study of Pregabalin GLARS Tablet 150mg and IR Formulation After Multiple Dosing Under Fed Condition in Healthy Male Subjects","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2014-02","conditions":"Healthy","enrollment":24},{"nctId":"NCT02103686","phase":"PHASE1","title":"Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2012-11","conditions":"Healthy","enrollment":30},{"nctId":"NCT02103647","phase":"PHASE1","title":"Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation","status":"COMPLETED","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2013-05","conditions":"Healthy","enrollment":24},{"nctId":"NCT01635751","phase":"PHASE1","title":"A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects","status":"COMPLETED","sponsor":"GL Pharm Tech Corporation","startDate":"2012-10","conditions":"Healthy","enrollment":30},{"nctId":"NCT00944697","phase":"PHASE2","title":"A Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2009-07","conditions":"Moderate to Severe Pain Due to Diabetic Polyneuropathy","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pregabalin Release Tablets","genericName":"Pregabalin Release Tablets","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury pain), Partial-onset seizures (adjunctive therapy), Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}